What We Know About Stage II and III Colon Cancer: It’s Still Not Enough Alberto PucciniMartin D. BergerHeinz-Josef Lenz Review Article 15 May 2017 Pages: 265 - 275
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors César SerranoSuzanne GeorgeJoan Carles Review Article 07 May 2017 Pages: 277 - 288
Cancer Immunotherapy with Cytokine-Induced Killer Cells Juan J. Mata-MolanesManuel Sureda GonzálezAntonio Brugarolas Masllorens Review Article 04 May 2017 Pages: 289 - 299
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management Caroline Prieux-KlotzMarie DiorRomain Coriat Current Opinion 24 May 2017 Pages: 301 - 308
Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis Xiu-Wei ZhangYu-Xiang MaChong-An Xu Systematic Review 29 March 2017 Pages: 309 - 321
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies Trisha M. Wise-DraperGanesh MoorthyJohn C. Morris Original Research Article Open access 29 March 2017 Pages: 323 - 332
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma Brian I. RiniVictor GruenwaldThomas E. Hutson Original Research Article 30 March 2017 Pages: 333 - 340
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients Yuji MishimaSatoshi MatsusakaKiyohiko Hatake Original Research Article 15 May 2017 Pages: 341 - 351
CRNDE Expression Positively Correlates with EGFR Activation and Modulates Glioma Cell Growth Karrie Mei-Yee KiangXiao-Qin ZhangGilberto Ka-Kit Leung Original Research Article 11 May 2017 Pages: 353 - 363
Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma Fanny GarlanBenoit BlanchetAudrey Thomas-Schoemann Short Communication 19 May 2017 Pages: 365 - 371
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Esther S. KimLesley J. Scott Adis Drug Evaluation 09 May 2017 Pages: 373 - 383
Erratum to: Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report Andrew J. DooleyAvinash GuptaMark R. Middleton Erratum 28 March 2017 Pages: 385 - 385